Altre lingue Paradigm Biopharmaceuticals Limited

Azioni

PAR

AU000000PAR5

Tempo differito Australian S.E. Altri mercati azionari 07:54:52 21/05/2024			Variaz. 5gg	Var. 1 gen.
0,245 ^AUD	-5,77%		-10,71%	-41,18%

28/02	Paradigm Biopharmaceuticals Limited riporta i risultati degli utili per il semestre terminato il 31 dicembre 2023	CI
12/02	Lo studio sul pentosan polisolfato di sodio iniettabile di Paradigm Biopharma raggiunge l'endpoint	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program	19/04
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02
Paradigm Biopharma's Injectable Pentosan Polysulfate Sodium Trial Reaches Endpoint	12/02
Paradigm Biopharmaceuticals Secures AU$7 Million R&D Tax Incentive Rebate for Fiscal Year 2023; Shares Rally 9%	07/02
Paradigm Biopharmaceuticals Opens Retail Entitlement Offer	06/11
Paradigm Biopharmaceuticals Raising AU$30 Million for Clinical Trial	30/10/23
Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately	20/10/23
Paradigm Biopharmaceuticals Validates Cartilage Preservation in Knee Osteoarthritis Trial	18/10/23
Paradigm Biopharmaceuticals Confirms Effectivity of Pain Medication in Osteoarthritis Trial	10/10/23
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/08/23
Paradigm Biopharmaceuticals Validates Efficacy of Anti-Inflammatory Medication in Canine Trial	02/06/23
Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up	11/04/23
Paradigm Biopharmaceuticals Announces Phase 2 Trial in Osteoarthritis Shows Signs of Disease Modification At 6-Month Follow-Up	11/04/23
Paradigm Biopharmaceuticals Limited Announces Injectable PPS Demonstrates Multiple Signals of A DMOAD in PARA_OA_008 Phase 2 Clinical Study	04/04/23
Paradigm Biopharmaceuticals Secures European Ethics Approval for Knee Osteoarthritis Trial	14/03/23
Paradigm Biopharmaceuticals Ltd Receives European Regulatory and Ethics Approval for the Pivotal PARA_OA_002 Global Clinical Trial	13/03/23
Starpharma Appoints CFO	03/03/23
Paradigm Biopharmaceuticals Names Interim CFO	03/03/23
Paradigm Biopharmaceuticals Limited Announces the Change of Chief Financial Officer	02/03/23
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022	26/02/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Paradigm Biopharmaceuticals Limited

Azioni

PAR

AU000000PAR5

Altre lingue

Filtri